Mark Parta1, Corin Kelly2, Nana Kwatemaa2, Narda Theobald2, Diane Hilligoss2, Jing Qin3, Douglas B Kuhns4, Christa Zerbe5, Steven M Holland5,6, Harry Malech2, Elizabeth M Kang2. 1. Clinical Research Directorate, Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland, 21702, USA. mark.parta@nih.gov. 2. Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA. 3. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, USA. 4. Applied Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702, USA. 5. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA. 6. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
Abstract
PURPOSE: The purpose of this study was to evaluate engraftment and adverse events with a conditioning and prophylactic regimen intended to achieve high rates of engraftment with minimal graft-versus-host disease (GVHD) in allogeneic transplantation for chronic granulomatous disease in a single center. METHODS: Forty patients, 37 male, with chronic granulomatous disease were transplanted. Transplant products were matched sibling peripheral blood stem cells (PBSCs) in four and matched unrelated donor (MUD) bone marrow in three, and one patient received mismatched unrelated PBSCs. Thirty-two patients received MUD PBSCs. All patients received a conditioning regimen of busulfan/alemtuzumab (with low-dose total body irradiation for MUD recipients) with sirolimus graft-versus-host disease prophylaxis. RESULTS: Engraftment occured in 38/40 recipients (95%). Acute or chronic GVHD occurred in 18 (45%) and 5 (12.5%), respectively, with 6 episodes of grades III-IV and/or steroid refractory GVHD. Overall survival was 33/40 (82.5%) and event-free survival was 30/40 (80%). Successful engraftment was associated with myeloid and NK cell, but not CD3+ chimerism. Myeloid engraftment was greater than 70% in 30/32 recipients at mean follow-up of 3.4 years. Evidence of persistent immunodeficiency was not seen in successful transplants. Attempts to rescue failed or poorly functioning grafts were associated with unacceptable morbidity and mortality. CONCLUSIONS: A reduced-intensity allogeneic transplant protocol based on alemtuzumab and busulfan with sirolimus GVHD prophylaxis produced high rates of successful engraftment and minimal regimen-related toxicity. Prolonged clinical follow-up has confirmed its efficacy in ameliorating CGD-related disease. Outcomes were not acceptable with donor cell infusion rescue of cause with poor graft function.
PURPOSE: The purpose of this study was to evaluate engraftment and adverse events with a conditioning and prophylactic regimen intended to achieve high rates of engraftment with minimal graft-versus-host disease (GVHD) in allogeneic transplantation for chronic granulomatous disease in a single center. METHODS: Forty patients, 37 male, with chronic granulomatous disease were transplanted. Transplant products were matched sibling peripheral blood stem cells (PBSCs) in four and matched unrelated donor (MUD) bone marrow in three, and one patient received mismatched unrelated PBSCs. Thirty-two patients received MUD PBSCs. All patients received a conditioning regimen of busulfan/alemtuzumab (with low-dose total body irradiation for MUD recipients) with sirolimusgraft-versus-host disease prophylaxis. RESULTS: Engraftment occured in 38/40 recipients (95%). Acute or chronic GVHD occurred in 18 (45%) and 5 (12.5%), respectively, with 6 episodes of grades III-IV and/or steroid refractory GVHD. Overall survival was 33/40 (82.5%) and event-free survival was 30/40 (80%). Successful engraftment was associated with myeloid and NK cell, but not CD3+ chimerism. Myeloid engraftment was greater than 70% in 30/32 recipients at mean follow-up of 3.4 years. Evidence of persistent immunodeficiency was not seen in successful transplants. Attempts to rescue failed or poorly functioning grafts were associated with unacceptable morbidity and mortality. CONCLUSIONS: A reduced-intensity allogeneic transplant protocol based on alemtuzumab and busulfan with sirolimusGVHD prophylaxis produced high rates of successful engraftment and minimal regimen-related toxicity. Prolonged clinical follow-up has confirmed its efficacy in ameliorating CGD-related disease. Outcomes were not acceptable with donor cell infusion rescue of cause with poor graft function.
Authors: Jonathan D Powell; Courtney Fitzhugh; Elizabeth M Kang; Mathew Hsieh; Ronald H Schwartz; John F Tisdale Journal: Transplantation Date: 2005-12-15 Impact factor: 4.939
Authors: Daniel Zecher; Qi Li; Martin H Oberbarnscheidt; Anthony J Demetris; Warren D Shlomchik; David M Rothstein; Fadi G Lakkis Journal: J Immunol Date: 2010-05-14 Impact factor: 5.422
Authors: S Breuer; S Preuner; G Fritsch; H Daxberger; M Koenig; U Poetschger; A Lawitschka; C Peters; G Mann; T Lion; S Matthes-Martin Journal: Leukemia Date: 2011-09-16 Impact factor: 11.528
Authors: Ronjon Chakraverty; Guillermo Orti; Michael Roughton; Jun Shen; Adele Fielding; Panagiotis Kottaridis; Donald Milligan; Matthew Collin; Charles Crawley; Peter Johnson; Andrew Clark; Anne Parker; Adrian Bloor; Ruth Pettengell; John Snowden; Andrew Pettitt; Richard Clark; Geoff Hale; Karl Peggs; Kirsty Thomson; Emma Morris; Stephen Mackinnon Journal: Blood Date: 2010-06-29 Impact factor: 22.113
Authors: Matthew M Hsieh; Elizabeth M Kang; Courtney D Fitzhugh; M Beth Link; Charles D Bolan; Roger Kurlander; Richard W Childs; Griffin P Rodgers; Jonathan D Powell; John F Tisdale Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Anders Åhlin; Jakob Fugeläng; Martin de Boer; Olle Ringden; Anders Fasth; Jacek Winiarski Journal: Acta Paediatr Date: 2013-09-10 Impact factor: 2.299
Authors: Beatriz Morillo-Gutierrez; Rita Beier; Kanchan Rao; Lauri Burroughs; Ansgar Schulz; Anna-Maria Ewins; Brenda Gibson; Petr Sedlacek; Ladislav Krol; Brigitte Strahm; Irina Zaidman; Krzysztof Kalwak; Julie-An Talano; Ann Woolfrey; Chris Fraser; Isabelle Meyts; Ingo Müller; Jacek Wachowiak; Maria Ester Bernardo; Paul Veys; Karl-Walter Sykora; Andrew R Gennery; Mary Slatter Journal: Blood Date: 2016-05-23 Impact factor: 22.113
Authors: John Audley; Emily F Gliniewicz; Kol A Zarember; Hanna S Hong; Gal Wald; Douglas B Kuhns; Elizabeth Kang; Harry L Malech; Anthony F Suffredini; Robert J Noveck; Mark J Dinubile; Susan L Levinson; Thomas P Stossel; John I Gallin Journal: Inflammation Date: 2020-09-04 Impact factor: 4.092
Authors: T Barkai; R Somech; A Broides; R Gavrieli; B Wolach; N Marcus; D Hagin; T Stauber Journal: Clin Exp Immunol Date: 2020-07-13 Impact factor: 4.330
Authors: Monica S Thakar; Larisa Broglie; Brent Logan; Andrew Artz; Nancy Bunin; Lauri M Burroughs; Caitrin Fretham; David A Jacobsohn; Alison W Loren; Joanne Kurtzberg; Caridad A Martinez; Shin Mineishi; Adam S Nelson; Ann Woolfrey; Marcelo C Pasquini; Mohamed L Sorror Journal: Blood Date: 2018-12-13 Impact factor: 22.113
Authors: Rebecca A Marsh; Jennifer W Leiding; Brent R Logan; Linda M Griffith; Danielle E Arnold; Elie Haddad; E Liana Falcone; Ziyan Yin; Kadam Patel; Erin Arbuckle; Jack J Bleesing; Kathleen E Sullivan; Jennifer Heimall; Lauri M Burroughs; Suzanne Skoda-Smith; Shanmuganathan Chandrakasan; Lolie C Yu; Benjamin R Oshrine; Geoffrey D E Cuvelier; Monica S Thakar; Karin Chen; Pierre Teira; Shalini Shenoy; Rachel Phelan; Lisa R Forbes; Deepak Chellapandian; Blachy J Dávila Saldaña; Ami J Shah; Katja G Weinacht; Avni Joshi; Farid Boulad; Troy C Quigg; Christopher C Dvorak; Debi Grossman; Troy Torgerson; Pamela Graham; Vinod Prasad; Alan Knutsen; Hey Chong; Holly Miller; M Teresa de la Morena; Kenneth DeSantes; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Elizabeth Stenger; Sung-Yun Pai; John M Routes; Jennifer M Puck; Neena Kapoor; Michael A Pulsipher; Harry L Malech; Suhag Parikh; Elizabeth M Kang Journal: J Clin Immunol Date: 2019-08-02 Impact factor: 8.317